BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 12574957)

  • 21. Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia.
    Das M; Saikia TK; Advani SH; Parikh PM; Tawde S
    Bone Marrow Transplant; 2003 Jul; 32(2):125-9. PubMed ID: 12838275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT).
    Bacigalupo A
    Bone Marrow Transplant; 2002 Feb; 29(3):191-5. PubMed ID: 11859390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Non-myeloablative allogeneic stem cell transplantation].
    Dalgaard J; Fløisand Y; Stenersen M; Egeland T; Brinch L
    Tidsskr Nor Laegeforen; 2007 Mar; 127(6):721-4. PubMed ID: 17363982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
    Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease.
    Yanada M; Naoe T; Iida H; Sakamaki H; Sakura T; Kanamori H; Kodera Y; Okamoto S; Kanda Y; Sao H; Asai O; Nakai K; Maruta A; Kishi K; Furukawa T; Atsuta Y; Yamamoto K; Tanaka J; Takahashi S
    Bone Marrow Transplant; 2005 Nov; 36(10):867-72. PubMed ID: 16113659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic stem cell transplantation after reduced-intensity conditioning for acute myeloid leukaemia: impact of chronic graft-versus-host disease.
    Valcárcel D; Martino R; Piñana JL; Sierra J
    Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S35-7. PubMed ID: 19561412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder.
    Johansson JE; Remberger M; Lazarevic VLj; Hallböök H; Wahlin A; Kimby E; Juliusson G; Omar H; Hägglund H
    Bone Marrow Transplant; 2011 Jun; 46(6):870-5. PubMed ID: 20956959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
    Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
    Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
    Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic haematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versus-myeloma effect.
    Zeiser R; Finke J
    Eur J Cancer; 2006 Jul; 42(11):1601-11. PubMed ID: 16759847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advantages and limitations of (non-)myeloablative allogeneic stem cell transplantation.
    Huugen D; Schouten HC; Bos GM
    Neth J Med; 2002 May; 60(4):162-9. PubMed ID: 12164394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model.
    Vanclée A; Lutgens LC; Oving EB; Deutz NE; Gijbels MJ; Schouten HC; Bos GM
    Bone Marrow Transplant; 2005 Nov; 36(10):907-15. PubMed ID: 16151417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases.
    Satwani P; Cooper N; Rao K; Veys P; Amrolia P
    Bone Marrow Transplant; 2008 Jan; 41(2):173-82. PubMed ID: 18037944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning.
    Steiner M; Matthes-Martin S; Attarbaschi A; Minkov M; Grois N; Unger E; Holter W; Vormoor J; Wawer A; Ouachee M; Woessmann W; Gadner H
    Bone Marrow Transplant; 2005 Aug; 36(3):215-25. PubMed ID: 15937510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced-intensity allogeneic stem cell transplantation.
    Bearman SI
    Curr Hematol Rep; 2003 Jul; 2(4):277-86. PubMed ID: 12901324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immune reconstitution after allogeneic stem cell transplantation using nonmyeloablative or reduced-intensity conditioning regimen].
    Nakai K
    Nihon Rinsho; 2003 Sep; 61(9):1542-8. PubMed ID: 14515721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
    Pérez-Simón JA; Díez-Campelo M; Martino R; Brunet S; Urbano A; Caballero MD; de León A; Valcárcel D; Carreras E; del Cañizo MC; López-Fidalgo J; Sierra J; San Miguel JF
    Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
    Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
    Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
    Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
    Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
    Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.